Yearly Archives: 2017

The Growth of Orphan Drugs

In 1983, the Orphan Drug Act was enacted to incentivize pharmaceutical manufacturers to research and develop treatments for rare diseases and conditions, which are generally defined as those that affect fewer than 200,000 people. Since this law, the industry has …

Using TherigySTM to Satisfy URAC Standards

Following the recent URAC Specialty Pharmacy v3.0 Accreditation webinar, we sent attendees a post-event survey. We gathered results. We took a close look. And, we are responding. Many of you fine folks asked us how you can use TherigySTM™ to …

DIR Fees: The Clawback Trend

Direct and indirect remuneration (DIR) fees are one of the most controversial topics in the pharmacy industry. Proponents of DIR fees state that they help to promote quality and value among pharmacy operations, while helping to keep premiums low for …